nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Pain—Ibandronate—osteoporosis	0.00133	0.00157	CcSEcCtD
Apraclonidine—Constipation—Ibandronate—osteoporosis	0.00133	0.00157	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.00133	0.00157	CcSEcCtD
Apraclonidine—Pruritus—Etidronic acid—osteoporosis	0.00133	0.00156	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Estropipate—osteoporosis	0.00132	0.00156	CcSEcCtD
Apraclonidine—Mental disorder—Conjugated Estrogens—osteoporosis	0.00132	0.00156	CcSEcCtD
Apraclonidine—Feeling abnormal—Alendronate—osteoporosis	0.00132	0.00155	CcSEcCtD
Apraclonidine—Oedema—Ethinyl Estradiol—osteoporosis	0.00131	0.00155	CcSEcCtD
Apraclonidine—Erythema—Conjugated Estrogens—osteoporosis	0.00131	0.00155	CcSEcCtD
Apraclonidine—Dry mouth—Risedronate—osteoporosis	0.00131	0.00154	CcSEcCtD
Apraclonidine—Conjunctivitis—Estradiol—osteoporosis	0.00131	0.00154	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Alendronate—osteoporosis	0.0013	0.00154	CcSEcCtD
Apraclonidine—Infection—Ethinyl Estradiol—osteoporosis	0.0013	0.00154	CcSEcCtD
Apraclonidine—Pain—Calcitriol—osteoporosis	0.0013	0.00154	CcSEcCtD
Apraclonidine—Constipation—Calcitriol—osteoporosis	0.0013	0.00154	CcSEcCtD
Apraclonidine—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.00129	0.00152	CcSEcCtD
Apraclonidine—Tension—Conjugated Estrogens—osteoporosis	0.00129	0.00152	CcSEcCtD
Apraclonidine—Dysgeusia—Conjugated Estrogens—osteoporosis	0.00128	0.00152	CcSEcCtD
Apraclonidine—Vision blurred—Zoledronate—osteoporosis	0.00128	0.00152	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Raloxifene—osteoporosis	0.00128	0.00152	CcSEcCtD
Apraclonidine—Diarrhoea—Etidronic acid—osteoporosis	0.00128	0.00151	CcSEcCtD
Apraclonidine—Abdominal pain—Estropipate—osteoporosis	0.00128	0.00151	CcSEcCtD
Apraclonidine—Feeling abnormal—Ibandronate—osteoporosis	0.00128	0.00151	CcSEcCtD
Apraclonidine—Skin disorder—Ethinyl Estradiol—osteoporosis	0.00128	0.00151	CcSEcCtD
Apraclonidine—Nervousness—Conjugated Estrogens—osteoporosis	0.00127	0.0015	CcSEcCtD
Apraclonidine—Infection—Risedronate—osteoporosis	0.00127	0.0015	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Ibandronate—osteoporosis	0.00127	0.0015	CcSEcCtD
Apraclonidine—Myalgia—Pamidronate—osteoporosis	0.00127	0.0015	CcSEcCtD
Apraclonidine—Ill-defined disorder—Zoledronate—osteoporosis	0.00126	0.00149	CcSEcCtD
Apraclonidine—Abdominal pain—Alendronate—osteoporosis	0.00126	0.00149	CcSEcCtD
Apraclonidine—Nervous system disorder—Risedronate—osteoporosis	0.00126	0.00148	CcSEcCtD
Apraclonidine—Discomfort—Pamidronate—osteoporosis	0.00125	0.00148	CcSEcCtD
Apraclonidine—Skin disorder—Risedronate—osteoporosis	0.00124	0.00147	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Calcitriol—osteoporosis	0.00124	0.00147	CcSEcCtD
Apraclonidine—Abdominal pain—Raloxifene—osteoporosis	0.00124	0.00146	CcSEcCtD
Apraclonidine—Vision blurred—Conjugated Estrogens—osteoporosis	0.00124	0.00146	CcSEcCtD
Apraclonidine—Malaise—Zoledronate—osteoporosis	0.00123	0.00145	CcSEcCtD
Apraclonidine—Abdominal pain—Ibandronate—osteoporosis	0.00123	0.00145	CcSEcCtD
Apraclonidine—Syncope—Zoledronate—osteoporosis	0.00122	0.00144	CcSEcCtD
Apraclonidine—Oedema—Pamidronate—osteoporosis	0.00122	0.00144	CcSEcCtD
Apraclonidine—Infection—Pamidronate—osteoporosis	0.00121	0.00143	CcSEcCtD
Apraclonidine—Rhinitis—Estradiol—osteoporosis	0.00121	0.00143	CcSEcCtD
Apraclonidine—Haemorrhage—Estradiol—osteoporosis	0.00121	0.00142	CcSEcCtD
Apraclonidine—Palpitations—Zoledronate—osteoporosis	0.0012	0.00142	CcSEcCtD
Apraclonidine—Abdominal pain—Calcitriol—osteoporosis	0.0012	0.00142	CcSEcCtD
Apraclonidine—Pharyngitis—Estradiol—osteoporosis	0.0012	0.00141	CcSEcCtD
Apraclonidine—Hypersensitivity—Estropipate—osteoporosis	0.00119	0.00141	CcSEcCtD
Apraclonidine—Nervous system disorder—Pamidronate—osteoporosis	0.00119	0.00141	CcSEcCtD
Apraclonidine—Vomiting—Etidronic acid—osteoporosis	0.00119	0.00141	CcSEcCtD
Apraclonidine—Oedema peripheral—Estradiol—osteoporosis	0.00119	0.0014	CcSEcCtD
Apraclonidine—Dermatitis—Etidronic acid—osteoporosis	0.00118	0.00139	CcSEcCtD
Apraclonidine—Syncope—Conjugated Estrogens—osteoporosis	0.00118	0.00139	CcSEcCtD
Apraclonidine—Hypersensitivity—Alendronate—osteoporosis	0.00118	0.00139	CcSEcCtD
Apraclonidine—Headache—Etidronic acid—osteoporosis	0.00117	0.00139	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Risedronate—osteoporosis	0.00117	0.00138	CcSEcCtD
Apraclonidine—Asthenia—Estropipate—osteoporosis	0.00116	0.00137	CcSEcCtD
Apraclonidine—Visual impairment—Estradiol—osteoporosis	0.00116	0.00137	CcSEcCtD
Apraclonidine—Chest pain—Zoledronate—osteoporosis	0.00116	0.00137	CcSEcCtD
Apraclonidine—Myalgia—Zoledronate—osteoporosis	0.00116	0.00137	CcSEcCtD
Apraclonidine—Palpitations—Conjugated Estrogens—osteoporosis	0.00116	0.00137	CcSEcCtD
Apraclonidine—Insomnia—Risedronate—osteoporosis	0.00116	0.00137	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.00115	0.00136	CcSEcCtD
Apraclonidine—Paraesthesia—Risedronate—osteoporosis	0.00115	0.00136	CcSEcCtD
Apraclonidine—Pruritus—Estropipate—osteoporosis	0.00115	0.00135	CcSEcCtD
Apraclonidine—Discomfort—Zoledronate—osteoporosis	0.00115	0.00135	CcSEcCtD
Apraclonidine—Asthenia—Alendronate—osteoporosis	0.00114	0.00135	CcSEcCtD
Apraclonidine—Hypersensitivity—Ibandronate—osteoporosis	0.00114	0.00135	CcSEcCtD
Apraclonidine—Dyspnoea—Risedronate—osteoporosis	0.00114	0.00135	CcSEcCtD
Apraclonidine—Dry mouth—Zoledronate—osteoporosis	0.00113	0.00134	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.00113	0.00134	CcSEcCtD
Apraclonidine—Fatigue—Ethinyl Estradiol—osteoporosis	0.00113	0.00134	CcSEcCtD
Apraclonidine—Pruritus—Alendronate—osteoporosis	0.00113	0.00133	CcSEcCtD
Apraclonidine—Eye disorder—Estradiol—osteoporosis	0.00113	0.00133	CcSEcCtD
Apraclonidine—Constipation—Ethinyl Estradiol—osteoporosis	0.00112	0.00133	CcSEcCtD
Apraclonidine—Hypersensitivity—Calcitriol—osteoporosis	0.00112	0.00132	CcSEcCtD
Apraclonidine—Myalgia—Conjugated Estrogens—osteoporosis	0.00112	0.00132	CcSEcCtD
Apraclonidine—Chest pain—Conjugated Estrogens—osteoporosis	0.00112	0.00132	CcSEcCtD
Apraclonidine—Asthenia—Ibandronate—osteoporosis	0.00111	0.00132	CcSEcCtD
Apraclonidine—Nausea—Etidronic acid—osteoporosis	0.00111	0.00131	CcSEcCtD
Apraclonidine—Oedema—Zoledronate—osteoporosis	0.00111	0.00131	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.00111	0.00131	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.00111	0.00131	CcSEcCtD
Apraclonidine—Diarrhoea—Estropipate—osteoporosis	0.00111	0.00131	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Risedronate—osteoporosis	0.00111	0.00131	CcSEcCtD
Apraclonidine—Infection—Zoledronate—osteoporosis	0.0011	0.0013	CcSEcCtD
Apraclonidine—Fatigue—Risedronate—osteoporosis	0.0011	0.0013	CcSEcCtD
Apraclonidine—Insomnia—Pamidronate—osteoporosis	0.0011	0.0013	CcSEcCtD
Apraclonidine—Pruritus—Ibandronate—osteoporosis	0.0011	0.0013	CcSEcCtD
Apraclonidine—Constipation—Risedronate—osteoporosis	0.00109	0.00129	CcSEcCtD
Apraclonidine—Pain—Risedronate—osteoporosis	0.00109	0.00129	CcSEcCtD
Apraclonidine—Angiopathy—Estradiol—osteoporosis	0.00109	0.00129	CcSEcCtD
Apraclonidine—Paraesthesia—Pamidronate—osteoporosis	0.00109	0.00129	CcSEcCtD
Apraclonidine—Diarrhoea—Alendronate—osteoporosis	0.00109	0.00129	CcSEcCtD
Apraclonidine—Asthenia—Calcitriol—osteoporosis	0.00109	0.00129	CcSEcCtD
Apraclonidine—Nervous system disorder—Zoledronate—osteoporosis	0.00109	0.00129	CcSEcCtD
Apraclonidine—Mediastinal disorder—Estradiol—osteoporosis	0.00109	0.00128	CcSEcCtD
Apraclonidine—Dyspnoea—Pamidronate—osteoporosis	0.00109	0.00128	CcSEcCtD
Apraclonidine—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.00108	0.00128	CcSEcCtD
Apraclonidine—Somnolence—Pamidronate—osteoporosis	0.00108	0.00128	CcSEcCtD
Apraclonidine—Skin disorder—Zoledronate—osteoporosis	0.00108	0.00127	CcSEcCtD
Apraclonidine—Pruritus—Calcitriol—osteoporosis	0.00108	0.00127	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.00107	0.00127	CcSEcCtD
Apraclonidine—Diarrhoea—Raloxifene—osteoporosis	0.00107	0.00127	CcSEcCtD
Apraclonidine—Dizziness—Estropipate—osteoporosis	0.00107	0.00126	CcSEcCtD
Apraclonidine—Oedema—Conjugated Estrogens—osteoporosis	0.00107	0.00126	CcSEcCtD
Apraclonidine—Infection—Conjugated Estrogens—osteoporosis	0.00106	0.00126	CcSEcCtD
Apraclonidine—Diarrhoea—Ibandronate—osteoporosis	0.00106	0.00125	CcSEcCtD
Apraclonidine—Mental disorder—Estradiol—osteoporosis	0.00106	0.00125	CcSEcCtD
Apraclonidine—Dizziness—Alendronate—osteoporosis	0.00106	0.00125	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Pamidronate—osteoporosis	0.00105	0.00124	CcSEcCtD
Apraclonidine—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.00105	0.00124	CcSEcCtD
Apraclonidine—Erythema—Estradiol—osteoporosis	0.00105	0.00124	CcSEcCtD
Apraclonidine—Fatigue—Pamidronate—osteoporosis	0.00105	0.00124	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Risedronate—osteoporosis	0.00105	0.00124	CcSEcCtD
Apraclonidine—Pain—Pamidronate—osteoporosis	0.00104	0.00123	CcSEcCtD
Apraclonidine—Constipation—Pamidronate—osteoporosis	0.00104	0.00123	CcSEcCtD
Apraclonidine—Diarrhoea—Calcitriol—osteoporosis	0.00104	0.00123	CcSEcCtD
Apraclonidine—Skin disorder—Conjugated Estrogens—osteoporosis	0.00104	0.00123	CcSEcCtD
Apraclonidine—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.00104	0.00123	CcSEcCtD
Apraclonidine—Dizziness—Raloxifene—osteoporosis	0.00104	0.00123	CcSEcCtD
Apraclonidine—Tension—Estradiol—osteoporosis	0.00103	0.00122	CcSEcCtD
Apraclonidine—Vomiting—Estropipate—osteoporosis	0.00103	0.00122	CcSEcCtD
Apraclonidine—Dysgeusia—Estradiol—osteoporosis	0.00103	0.00121	CcSEcCtD
Apraclonidine—Dizziness—Ibandronate—osteoporosis	0.00103	0.00121	CcSEcCtD
Apraclonidine—Dermatitis—Estropipate—osteoporosis	0.00102	0.0012	CcSEcCtD
Apraclonidine—Nervousness—Estradiol—osteoporosis	0.00102	0.0012	CcSEcCtD
Apraclonidine—Headache—Estropipate—osteoporosis	0.00102	0.0012	CcSEcCtD
Apraclonidine—Vomiting—Alendronate—osteoporosis	0.00101	0.0012	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.00101	0.0012	CcSEcCtD
Apraclonidine—Abdominal pain—Risedronate—osteoporosis	0.00101	0.00119	CcSEcCtD
Apraclonidine—Insomnia—Zoledronate—osteoporosis	0.00101	0.00119	CcSEcCtD
Apraclonidine—Dermatitis—Alendronate—osteoporosis	0.00101	0.00119	CcSEcCtD
Apraclonidine—Feeling abnormal—Pamidronate—osteoporosis	0.001	0.00118	CcSEcCtD
Apraclonidine—Headache—Alendronate—osteoporosis	0.001	0.00118	CcSEcCtD
Apraclonidine—Paraesthesia—Zoledronate—osteoporosis	0.000998	0.00118	CcSEcCtD
Apraclonidine—Vomiting—Raloxifene—osteoporosis	0.000998	0.00118	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Pamidronate—osteoporosis	0.000995	0.00118	CcSEcCtD
Apraclonidine—Dyspnoea—Zoledronate—osteoporosis	0.000991	0.00117	CcSEcCtD
Apraclonidine—Dermatitis—Raloxifene—osteoporosis	0.000989	0.00117	CcSEcCtD
Apraclonidine—Somnolence—Zoledronate—osteoporosis	0.000988	0.00117	CcSEcCtD
Apraclonidine—Vomiting—Ibandronate—osteoporosis	0.000988	0.00117	CcSEcCtD
Apraclonidine—Headache—Raloxifene—osteoporosis	0.000983	0.00116	CcSEcCtD
Apraclonidine—Dermatitis—Ibandronate—osteoporosis	0.000979	0.00116	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000975	0.00115	CcSEcCtD
Apraclonidine—Ill-defined disorder—Estradiol—osteoporosis	0.000974	0.00115	CcSEcCtD
Apraclonidine—Headache—Ibandronate—osteoporosis	0.000973	0.00115	CcSEcCtD
Apraclonidine—Insomnia—Conjugated Estrogens—osteoporosis	0.000968	0.00114	CcSEcCtD
Apraclonidine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000968	0.00114	CcSEcCtD
Apraclonidine—Vomiting—Calcitriol—osteoporosis	0.000967	0.00114	CcSEcCtD
Apraclonidine—Nausea—Estropipate—osteoporosis	0.000962	0.00114	CcSEcCtD
Apraclonidine—Abdominal pain—Pamidronate—osteoporosis	0.000962	0.00114	CcSEcCtD
Apraclonidine—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000961	0.00113	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Zoledronate—osteoporosis	0.00096	0.00113	CcSEcCtD
Apraclonidine—Fatigue—Zoledronate—osteoporosis	0.000959	0.00113	CcSEcCtD
Apraclonidine—Dermatitis—Calcitriol—osteoporosis	0.000958	0.00113	CcSEcCtD
Apraclonidine—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000954	0.00113	CcSEcCtD
Apraclonidine—Headache—Calcitriol—osteoporosis	0.000953	0.00112	CcSEcCtD
Apraclonidine—Somnolence—Conjugated Estrogens—osteoporosis	0.000952	0.00112	CcSEcCtD
Apraclonidine—Pain—Zoledronate—osteoporosis	0.000951	0.00112	CcSEcCtD
Apraclonidine—Constipation—Zoledronate—osteoporosis	0.000951	0.00112	CcSEcCtD
Apraclonidine—Nausea—Alendronate—osteoporosis	0.000948	0.00112	CcSEcCtD
Apraclonidine—Malaise—Estradiol—osteoporosis	0.000947	0.00112	CcSEcCtD
Apraclonidine—Hypersensitivity—Risedronate—osteoporosis	0.000943	0.00111	CcSEcCtD
Apraclonidine—Asthenia—Ethinyl Estradiol—osteoporosis	0.000942	0.00111	CcSEcCtD
Apraclonidine—Syncope—Estradiol—osteoporosis	0.000942	0.00111	CcSEcCtD
Apraclonidine—Nausea—Raloxifene—osteoporosis	0.000932	0.0011	CcSEcCtD
Apraclonidine—Pruritus—Ethinyl Estradiol—osteoporosis	0.000929	0.0011	CcSEcCtD
Apraclonidine—Palpitations—Estradiol—osteoporosis	0.000928	0.0011	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000924	0.00109	CcSEcCtD
Apraclonidine—Fatigue—Conjugated Estrogens—osteoporosis	0.000923	0.00109	CcSEcCtD
Apraclonidine—Nausea—Ibandronate—osteoporosis	0.000923	0.00109	CcSEcCtD
Apraclonidine—Asthenia—Risedronate—osteoporosis	0.000919	0.00108	CcSEcCtD
Apraclonidine—Feeling abnormal—Zoledronate—osteoporosis	0.000916	0.00108	CcSEcCtD
Apraclonidine—Pain—Conjugated Estrogens—osteoporosis	0.000916	0.00108	CcSEcCtD
Apraclonidine—Constipation—Conjugated Estrogens—osteoporosis	0.000916	0.00108	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Zoledronate—osteoporosis	0.000909	0.00107	CcSEcCtD
Apraclonidine—Pruritus—Risedronate—osteoporosis	0.000906	0.00107	CcSEcCtD
Apraclonidine—Nausea—Calcitriol—osteoporosis	0.000903	0.00107	CcSEcCtD
Apraclonidine—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000899	0.00106	CcSEcCtD
Apraclonidine—Hypersensitivity—Pamidronate—osteoporosis	0.000897	0.00106	CcSEcCtD
Apraclonidine—Chest pain—Estradiol—osteoporosis	0.000894	0.00106	CcSEcCtD
Apraclonidine—Myalgia—Estradiol—osteoporosis	0.000894	0.00106	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000888	0.00105	CcSEcCtD
Apraclonidine—Discomfort—Estradiol—osteoporosis	0.000883	0.00104	CcSEcCtD
Apraclonidine—Abdominal pain—Zoledronate—osteoporosis	0.000879	0.00104	CcSEcCtD
Apraclonidine—Diarrhoea—Risedronate—osteoporosis	0.000876	0.00103	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000875	0.00103	CcSEcCtD
Apraclonidine—Dry mouth—Estradiol—osteoporosis	0.000874	0.00103	CcSEcCtD
Apraclonidine—Asthenia—Pamidronate—osteoporosis	0.000873	0.00103	CcSEcCtD
Apraclonidine—Dizziness—Ethinyl Estradiol—osteoporosis	0.000868	0.00103	CcSEcCtD
Apraclonidine—Pruritus—Pamidronate—osteoporosis	0.000861	0.00102	CcSEcCtD
Apraclonidine—Oedema—Estradiol—osteoporosis	0.000857	0.00101	CcSEcCtD
Apraclonidine—Infection—Estradiol—osteoporosis	0.000851	0.001	CcSEcCtD
Apraclonidine—Dizziness—Risedronate—osteoporosis	0.000847	0.001	CcSEcCtD
Apraclonidine—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000846	0.000999	CcSEcCtD
Apraclonidine—Nervous system disorder—Estradiol—osteoporosis	0.00084	0.000992	CcSEcCtD
Apraclonidine—Vomiting—Ethinyl Estradiol—osteoporosis	0.000835	0.000986	CcSEcCtD
Apraclonidine—Diarrhoea—Pamidronate—osteoporosis	0.000833	0.000983	CcSEcCtD
Apraclonidine—Skin disorder—Estradiol—osteoporosis	0.000832	0.000982	CcSEcCtD
Apraclonidine—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000827	0.000977	CcSEcCtD
Apraclonidine—Headache—Ethinyl Estradiol—osteoporosis	0.000823	0.000971	CcSEcCtD
Apraclonidine—Hypersensitivity—Zoledronate—osteoporosis	0.000819	0.000967	CcSEcCtD
Apraclonidine—Vomiting—Risedronate—osteoporosis	0.000814	0.000961	CcSEcCtD
Apraclonidine—Dermatitis—Risedronate—osteoporosis	0.000807	0.000952	CcSEcCtD
Apraclonidine—Dizziness—Pamidronate—osteoporosis	0.000805	0.00095	CcSEcCtD
Apraclonidine—Headache—Risedronate—osteoporosis	0.000802	0.000947	CcSEcCtD
Apraclonidine—Asthenia—Zoledronate—osteoporosis	0.000798	0.000942	CcSEcCtD
Apraclonidine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000789	0.000931	CcSEcCtD
Apraclonidine—Pruritus—Zoledronate—osteoporosis	0.000787	0.000929	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000781	0.000922	CcSEcCtD
Apraclonidine—Nausea—Ethinyl Estradiol—osteoporosis	0.00078	0.000921	CcSEcCtD
Apraclonidine—Insomnia—Estradiol—osteoporosis	0.000775	0.000915	CcSEcCtD
Apraclonidine—Vomiting—Pamidronate—osteoporosis	0.000774	0.000914	CcSEcCtD
Apraclonidine—Paraesthesia—Estradiol—osteoporosis	0.000769	0.000908	CcSEcCtD
Apraclonidine—Asthenia—Conjugated Estrogens—osteoporosis	0.000768	0.000907	CcSEcCtD
Apraclonidine—Dermatitis—Pamidronate—osteoporosis	0.000767	0.000905	CcSEcCtD
Apraclonidine—Dyspnoea—Estradiol—osteoporosis	0.000764	0.000902	CcSEcCtD
Apraclonidine—Headache—Pamidronate—osteoporosis	0.000763	0.0009	CcSEcCtD
Apraclonidine—Somnolence—Estradiol—osteoporosis	0.000762	0.000899	CcSEcCtD
Apraclonidine—Diarrhoea—Zoledronate—osteoporosis	0.000761	0.000898	CcSEcCtD
Apraclonidine—Nausea—Risedronate—osteoporosis	0.000761	0.000898	CcSEcCtD
Apraclonidine—Pruritus—Conjugated Estrogens—osteoporosis	0.000757	0.000894	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Estradiol—osteoporosis	0.00074	0.000873	CcSEcCtD
Apraclonidine—Fatigue—Estradiol—osteoporosis	0.000739	0.000872	CcSEcCtD
Apraclonidine—Dizziness—Zoledronate—osteoporosis	0.000735	0.000868	CcSEcCtD
Apraclonidine—Pain—Estradiol—osteoporosis	0.000733	0.000865	CcSEcCtD
Apraclonidine—Constipation—Estradiol—osteoporosis	0.000733	0.000865	CcSEcCtD
Apraclonidine—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000733	0.000865	CcSEcCtD
Apraclonidine—Nausea—Pamidronate—osteoporosis	0.000723	0.000854	CcSEcCtD
Apraclonidine—Dizziness—Conjugated Estrogens—osteoporosis	0.000708	0.000836	CcSEcCtD
Apraclonidine—Vomiting—Zoledronate—osteoporosis	0.000707	0.000835	CcSEcCtD
Apraclonidine—Feeling abnormal—Estradiol—osteoporosis	0.000706	0.000834	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Estradiol—osteoporosis	0.000701	0.000827	CcSEcCtD
Apraclonidine—Dermatitis—Zoledronate—osteoporosis	0.0007	0.000827	CcSEcCtD
Apraclonidine—Headache—Zoledronate—osteoporosis	0.000697	0.000822	CcSEcCtD
Apraclonidine—Vomiting—Conjugated Estrogens—osteoporosis	0.000681	0.000804	CcSEcCtD
Apraclonidine—Abdominal pain—Estradiol—osteoporosis	0.000677	0.0008	CcSEcCtD
Apraclonidine—Dermatitis—Conjugated Estrogens—osteoporosis	0.000674	0.000796	CcSEcCtD
Apraclonidine—Headache—Conjugated Estrogens—osteoporosis	0.000671	0.000792	CcSEcCtD
Apraclonidine—Nausea—Zoledronate—osteoporosis	0.00066	0.00078	CcSEcCtD
Apraclonidine—Nausea—Conjugated Estrogens—osteoporosis	0.000636	0.000751	CcSEcCtD
Apraclonidine—Hypersensitivity—Estradiol—osteoporosis	0.000631	0.000745	CcSEcCtD
Apraclonidine—Asthenia—Estradiol—osteoporosis	0.000615	0.000726	CcSEcCtD
Apraclonidine—Pruritus—Estradiol—osteoporosis	0.000606	0.000716	CcSEcCtD
Apraclonidine—Diarrhoea—Estradiol—osteoporosis	0.000586	0.000692	CcSEcCtD
Apraclonidine—Dizziness—Estradiol—osteoporosis	0.000567	0.000669	CcSEcCtD
Apraclonidine—Vomiting—Estradiol—osteoporosis	0.000545	0.000643	CcSEcCtD
Apraclonidine—Dermatitis—Estradiol—osteoporosis	0.00054	0.000637	CcSEcCtD
Apraclonidine—Headache—Estradiol—osteoporosis	0.000537	0.000634	CcSEcCtD
Apraclonidine—Nausea—Estradiol—osteoporosis	0.000509	0.000601	CcSEcCtD
Apraclonidine—ADRA2A—Metabolism—GPD2—osteoporosis	0.000236	0.00154	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000231	0.00151	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CALCR—osteoporosis	0.000231	0.00151	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PTH1R—osteoporosis	0.000231	0.00151	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—PTH—osteoporosis	0.000227	0.00148	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—OXCT1—osteoporosis	0.000226	0.00148	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CA2—osteoporosis	0.000226	0.00148	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SOST—osteoporosis	0.000224	0.00146	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CNR2—osteoporosis	0.000221	0.00144	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PTH—osteoporosis	0.00022	0.00144	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—MGLL—osteoporosis	0.00022	0.00144	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ATIC—osteoporosis	0.000216	0.00141	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PNP—osteoporosis	0.000216	0.00141	CbGpPWpGaD
Apraclonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000215	0.00141	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CNR2—osteoporosis	0.000215	0.0014	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SOST—osteoporosis	0.000208	0.00136	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—IGF1—osteoporosis	0.000207	0.00136	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PTH—osteoporosis	0.000206	0.00135	CbGpPWpGaD
Apraclonidine—ADRA2A—G alpha (i) signalling events—POMC—osteoporosis	0.000205	0.00134	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PTH1R—osteoporosis	0.000202	0.00132	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CALCR—osteoporosis	0.000202	0.00132	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—WNT1—osteoporosis	0.000202	0.00132	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—PTHLH—osteoporosis	0.000201	0.00131	CbGpPWpGaD
Apraclonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000201	0.00131	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CNR2—osteoporosis	0.000201	0.00131	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PTH—osteoporosis	0.000198	0.0013	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MGLL—osteoporosis	0.000197	0.00129	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CNR2—osteoporosis	0.000193	0.00126	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—LRP5—osteoporosis	0.000192	0.00126	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—WNT1—osteoporosis	0.000189	0.00123	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTH1R—osteoporosis	0.000188	0.00123	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CALCR—osteoporosis	0.000188	0.00123	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—PTHLH—osteoporosis	0.000188	0.00123	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—IDH2—osteoporosis	0.000187	0.00122	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PTH—osteoporosis	0.000184	0.0012	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MGLL—osteoporosis	0.000184	0.0012	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—LRP6—osteoporosis	0.000184	0.0012	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CA2—osteoporosis	0.000183	0.0012	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—OXCT1—osteoporosis	0.000183	0.0012	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PTHLH—osteoporosis	0.000183	0.00119	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PTH—osteoporosis	0.00018	0.00118	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—LRP5—osteoporosis	0.000179	0.00117	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CNR2—osteoporosis	0.000179	0.00117	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—MGLL—osteoporosis	0.000179	0.00117	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—CALCA—osteoporosis	0.000177	0.00116	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CYP27A1—osteoporosis	0.000176	0.00115	CbGpPWpGaD
Apraclonidine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000176	0.00115	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CNR2—osteoporosis	0.000175	0.00115	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—LRP6—osteoporosis	0.000172	0.00112	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ACP5—osteoporosis	0.000171	0.00112	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PTHLH—osteoporosis	0.000171	0.00112	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PTH—osteoporosis	0.000167	0.00109	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—CALCA—osteoporosis	0.000165	0.00108	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—WNT1—osteoporosis	0.000165	0.00108	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PTHLH—osteoporosis	0.000164	0.00107	CbGpPWpGaD
Apraclonidine—ADRA2B—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	0.000164	0.00107	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR ligand binding—POMC—osteoporosis	0.000164	0.00107	CbGpPWpGaD
Apraclonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000163	0.00107	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CNR2—osteoporosis	0.000163	0.00107	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—CALCA—osteoporosis	0.000161	0.00105	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MGLL—osteoporosis	0.000161	0.00105	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—TPI1—osteoporosis	0.000159	0.00104	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LRP5—osteoporosis	0.000157	0.00103	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TLN1—osteoporosis	0.000155	0.00101	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—WNT1—osteoporosis	0.000153	0.001	CbGpPWpGaD
Apraclonidine—ADRA2C—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	0.000153	0.001	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—POMC—osteoporosis	0.000153	0.001	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PTHLH—osteoporosis	0.000153	0.000998	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—IDH2—osteoporosis	0.000152	0.000993	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—CALCA—osteoporosis	0.00015	0.000982	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LRP6—osteoporosis	0.00015	0.000981	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—P4HB—osteoporosis	0.000149	0.000977	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MGLL—osteoporosis	0.000149	0.000977	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PTHLH—osteoporosis	0.000149	0.000975	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GAPDH—osteoporosis	0.000147	0.000959	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LRP5—osteoporosis	0.000146	0.000953	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TLN1—osteoporosis	0.000145	0.000948	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—CALCA—osteoporosis	0.000145	0.000945	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—RAP1A—osteoporosis	0.000143	0.000934	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CYP27A1—osteoporosis	0.000143	0.000934	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—IGF1—osteoporosis	0.000141	0.000922	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LRP6—osteoporosis	0.000139	0.000912	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ACP5—osteoporosis	0.000139	0.000908	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PTHLH—osteoporosis	0.000138	0.000906	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—CALCA—osteoporosis	0.000134	0.000878	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—POMC—osteoporosis	0.000134	0.000875	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—P4HB—osteoporosis	0.000134	0.000875	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—IGF1—osteoporosis	0.000132	0.000861	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—CALCA—osteoporosis	0.000131	0.000858	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PTH—osteoporosis	0.00013	0.000851	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—TPI1—osteoporosis	0.000129	0.000844	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RAP1A—osteoporosis	0.000128	0.000837	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CNR2—osteoporosis	0.000127	0.000829	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TLN1—osteoporosis	0.000127	0.000829	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—ADCY5—osteoporosis	0.000126	0.000823	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—P4HB—osteoporosis	0.000125	0.000817	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NFATC1—osteoporosis	0.000125	0.000816	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	0.000124	0.000813	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—POMC—osteoporosis	0.000124	0.000813	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—DKK1—osteoporosis	0.000124	0.00081	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CALCA—osteoporosis	0.000122	0.000798	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PTH—osteoporosis	0.000122	0.000795	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—P4HB—osteoporosis	0.000121	0.000794	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RAP1A—osteoporosis	0.000119	0.000781	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—WNT1—osteoporosis	0.000119	0.00078	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GAPDH—osteoporosis	0.000119	0.000779	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CNR2—osteoporosis	0.000118	0.000775	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TLN1—osteoporosis	0.000118	0.00077	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—ADCY5—osteoporosis	0.000118	0.000769	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NFATC1—osteoporosis	0.000117	0.000762	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—RAP1A—osteoporosis	0.000116	0.000759	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—FGA—osteoporosis	0.000116	0.000759	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—DKK1—osteoporosis	0.000116	0.000756	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ENO1—osteoporosis	0.000115	0.000755	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—ADCY5—osteoporosis	0.000114	0.000748	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PSMA2—osteoporosis	0.000114	0.000744	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PSMA5—osteoporosis	0.000114	0.000744	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—WNT1—osteoporosis	0.000111	0.000728	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—P4HB—osteoporosis	0.000109	0.000715	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FGA—osteoporosis	0.000108	0.000709	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PTHLH—osteoporosis	0.000108	0.000705	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—BMP2—osteoporosis	0.000108	0.000705	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—IGF1—osteoporosis	0.000107	0.000699	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—ADCY5—osteoporosis	0.000107	0.000698	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PTH—osteoporosis	0.000106	0.000695	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—FGB—osteoporosis	0.000106	0.00069	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RAP1A—osteoporosis	0.000104	0.000683	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CNR2—osteoporosis	0.000104	0.000677	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	0.000103	0.000674	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—ADCY5—osteoporosis	0.000103	0.000672	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NFATC1—osteoporosis	0.000102	0.000666	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PSMA5—osteoporosis	0.000102	0.000666	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PSMA2—osteoporosis	0.000102	0.000666	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—P4HB—osteoporosis	0.000102	0.000664	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—DKK1—osteoporosis	0.000101	0.000661	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PTHLH—osteoporosis	0.000101	0.000659	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—BMP2—osteoporosis	0.000101	0.000659	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTH—osteoporosis	9.87e-05	0.000646	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FGB—osteoporosis	9.86e-05	0.000645	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—WNT1—osteoporosis	9.74e-05	0.000637	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RAP1A—osteoporosis	9.7e-05	0.000635	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CNR2—osteoporosis	9.62e-05	0.000629	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—ADCY5—osteoporosis	9.55e-05	0.000625	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PSMA2—osteoporosis	9.52e-05	0.000622	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PSMA5—osteoporosis	9.52e-05	0.000622	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CALCA—osteoporosis	9.49e-05	0.000621	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FGA—osteoporosis	9.47e-05	0.00062	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NFATC1—osteoporosis	9.47e-05	0.000619	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—DKK1—osteoporosis	9.39e-05	0.000614	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ENO1—osteoporosis	9.38e-05	0.000614	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—ADCY5—osteoporosis	9.33e-05	0.000611	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—POMC—osteoporosis	9.26e-05	0.000606	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PSMA5—osteoporosis	9.24e-05	0.000605	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PSMA2—osteoporosis	9.24e-05	0.000605	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CYP19A1—osteoporosis	9.23e-05	0.000604	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—WNT1—osteoporosis	9.05e-05	0.000592	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CALCA—osteoporosis	8.87e-05	0.00058	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PTHLH—osteoporosis	8.81e-05	0.000576	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—BMP2—osteoporosis	8.81e-05	0.000576	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGA—osteoporosis	8.8e-05	0.000576	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—ADCY5—osteoporosis	8.67e-05	0.000567	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—POMC—osteoporosis	8.65e-05	0.000566	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KL—osteoporosis	8.62e-05	0.000564	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FGB—osteoporosis	8.62e-05	0.000564	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—TGFB1—osteoporosis	8.45e-05	0.000553	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—POMC—osteoporosis	8.41e-05	0.00055	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PSMA2—osteoporosis	8.32e-05	0.000544	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PSMA5—osteoporosis	8.32e-05	0.000544	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6R—osteoporosis	8.2e-05	0.000536	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTHLH—osteoporosis	8.18e-05	0.000535	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—BMP2—osteoporosis	8.18e-05	0.000535	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KL—osteoporosis	8.05e-05	0.000527	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGB—osteoporosis	8.01e-05	0.000524	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—TGFB1—osteoporosis	7.89e-05	0.000516	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—POMC—osteoporosis	7.85e-05	0.000514	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CALCA—osteoporosis	7.75e-05	0.000507	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PSMA2—osteoporosis	7.73e-05	0.000506	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PSMA5—osteoporosis	7.73e-05	0.000506	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6R—osteoporosis	7.66e-05	0.000501	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—POMC—osteoporosis	7.56e-05	0.000495	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ADCY5—osteoporosis	7.54e-05	0.000493	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GPX1—osteoporosis	7.52e-05	0.000492	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CYP19A1—osteoporosis	7.5e-05	0.000491	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CALCA—osteoporosis	7.2e-05	0.000471	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KL—osteoporosis	7.04e-05	0.00046	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—POMC—osteoporosis	7.03e-05	0.000459	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—MTHFR—osteoporosis	6.94e-05	0.000454	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—POMC—osteoporosis	6.87e-05	0.000449	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ADCY5—osteoporosis	6.75e-05	0.000442	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6R—osteoporosis	6.7e-05	0.000438	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KL—osteoporosis	6.54e-05	0.000428	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SPP1—osteoporosis	6.53e-05	0.000427	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—TGFB1—osteoporosis	6.41e-05	0.000419	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—POMC—osteoporosis	6.38e-05	0.000417	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ADCY5—osteoporosis	6.31e-05	0.000413	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6R—osteoporosis	6.22e-05	0.000407	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ADCY5—osteoporosis	6.13e-05	0.000401	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GPX1—osteoporosis	6.11e-05	0.000399	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SPP1—osteoporosis	6.1e-05	0.000399	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IRS2—osteoporosis	5.91e-05	0.000386	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—LEP—osteoporosis	5.78e-05	0.000378	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—MTHFR—osteoporosis	5.64e-05	0.000369	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—POMC—osteoporosis	5.55e-05	0.000363	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ESR1—osteoporosis	5.52e-05	0.000361	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IRS2—osteoporosis	5.52e-05	0.000361	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ADCY5—osteoporosis	5.51e-05	0.000361	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—LEP—osteoporosis	5.4e-05	0.000353	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SPP1—osteoporosis	5.34e-05	0.000349	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IRS1—osteoporosis	5.16e-05	0.000337	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ESR1—osteoporosis	5.16e-05	0.000337	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADCY5—osteoporosis	5.12e-05	0.000335	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—POMC—osteoporosis	4.97e-05	0.000325	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SPP1—osteoporosis	4.96e-05	0.000324	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6R—osteoporosis	4.85e-05	0.000317	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IRS2—osteoporosis	4.82e-05	0.000316	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IRS1—osteoporosis	4.82e-05	0.000315	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IGF1—osteoporosis	4.78e-05	0.000312	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LEP—osteoporosis	4.72e-05	0.000309	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—POMC—osteoporosis	4.64e-05	0.000303	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6R—osteoporosis	4.53e-05	0.000296	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ESR1—osteoporosis	4.51e-05	0.000295	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—POMC—osteoporosis	4.51e-05	0.000295	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IRS2—osteoporosis	4.48e-05	0.000293	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IGF1—osteoporosis	4.46e-05	0.000292	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LEP—osteoporosis	4.39e-05	0.000287	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IRS1—osteoporosis	4.21e-05	0.000275	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ESR1—osteoporosis	4.19e-05	0.000274	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—POMC—osteoporosis	4.06e-05	0.000265	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6R—osteoporosis	3.96e-05	0.000259	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IRS1—osteoporosis	3.91e-05	0.000256	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF1—osteoporosis	3.9e-05	0.000255	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—POMC—osteoporosis	3.77e-05	0.000246	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6R—osteoporosis	3.68e-05	0.00024	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6—osteoporosis	3.65e-05	0.000239	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF1—osteoporosis	3.63e-05	0.000237	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6—osteoporosis	3.41e-05	0.000223	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6—osteoporosis	2.98e-05	0.000195	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MYC—osteoporosis	2.87e-05	0.000188	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TGFB1—osteoporosis	2.86e-05	0.000187	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6—osteoporosis	2.77e-05	0.000181	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MYC—osteoporosis	2.68e-05	0.000175	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TGFB1—osteoporosis	2.68e-05	0.000175	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MYC—osteoporosis	2.34e-05	0.000153	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TGFB1—osteoporosis	2.34e-05	0.000153	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MYC—osteoporosis	2.18e-05	0.000142	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TGFB1—osteoporosis	2.17e-05	0.000142	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6—osteoporosis	2.16e-05	0.000141	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6—osteoporosis	2.02e-05	0.000132	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6—osteoporosis	1.76e-05	0.000115	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6—osteoporosis	1.64e-05	0.000107	CbGpPWpGaD
